Predictors for an anti-tumor response to ICIs currently are high PD-L1 expression, microsatellite high (MSI-H) cancers, tumor-infiltrating lymphocytes (TILs) at the edge of the tumor, and a high mutational burden (TMB). Here, CD274 is linked to cancer.